SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a proprietary technology to produce fully human polyclonal antibodies without the need for human plasma donors, today announced Eddie J. Sullivan, PhD, President, CEO and Co-founder of SAB Biotherapeutics will serve an expert panelist during BIO Digital 2020 . The BIO International Convention, which has transitioned to a new and virtual event and
June 8, 2020
· 3 min read